



## **Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference**

August 6, 2020

STAMFORD, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 at 8:00 a.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at [www.CaraTherapeutics.com](http://www.CaraTherapeutics.com). An archived webcast recording will be available on the Cara website for approximately 30 days.

### **About Cara Therapeutics**

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Cara has successfully completed its Phase 2 trial of Oral KORSUVA for the treatment of pruritus in patients with CKD and is currently conducting Phase 2 trials of Oral KORSUVA in atopic dermatitis and primary biliary cholangitis patients with moderate-to-severe pruritus.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

### **INVESTOR CONTACT:**

Janhavi Mohite  
Stern Investor Relations, Inc.  
212-362-1200  
[janhavi.mohite@sternir.com](mailto:janhavi.mohite@sternir.com)

### **MEDIA CONTACT:**

Annie Starr  
6 Degrees  
973-415-8838  
[astarr@6degreespr.com](mailto:astarr@6degreespr.com)



Source: Cara Therapeutics, Inc.